Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11528671 | 0.88 | TDP1 (0.69) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL10749123 | 0.87 | TDP1 (0.67) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL1587314 | 0.87 | CYP1A2 (0.67) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL1587140 | 0.87 | CYP1A2 (0.67) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL12648664 | 0.87 | TDP1 (0.67) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL30673515 | 0.86 | CYP1A2 (0.67) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL13149011 | 0.86 | CYP1A2 (0.77) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL9854476 | 0.86 | CYP1A2 (0.70) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL10983705 | 0.84 | CYP1A2 (0.74) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| SCHEMBL11755634 | 0.84 | CYP1A2 (0.74) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152224-A1 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES | ALLERGAN, INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152224-A1 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES | PTGIS, PTGIR, PTGS1 | CYP1A2 1157/4885ADRB2 250/4885ADRB1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.